Nader Karayanni
Disclaimer: This post summarizes publicly available legal research for informational purposes only. It is not legal advice and does not create an attorney-client relationship. Laws, court rules, and ethics opinions vary by jurisdiction and change over time.
TL;DR
Prior expert deposition transcripts can be enormously valuable for expert vetting, cross-prep, and impeachment. But "valuable" and "reusable" are not the same thing.
Whether a litigation team may reuse a prior transcript in a new matter depends on where it came from, what restrictions attach to it, whether it contains protected health information, and what the team intends to do with it.
The answer is almost never a simple yes or no — it is a checklist of questions that should be answered before the transcript is uploaded, analyzed, shared, or cited.
Key Takeaways:
Discovering prior testimony exists is legally different from possessing, analyzing, or filing it.
Private, client-specific archives are much safer than pooled cross-customer transcript databases.
Protective orders can prohibit cross-matter reuse even if you lawfully received the transcript.
HIPAA can limit reuse of PHI-containing transcripts across cases.
Impeachment use and substantive evidentiary use are governed by different rules with different requirements.
Attorney ethics rules add another layer of restriction, particularly for transcripts from different clients or matters.
Rough draft transcripts and real-time feeds carry their own restrictions beyond certified final transcripts.
Why Prior Expert Transcripts Are So Valuable, and So Complicated
Litigation teams have long known that an expert's prior deposition testimony is one of the most useful tools in discovery and at trial. It can reveal how an expert handles aggressive questioning, where their methodology is vulnerable, how their opinions have shifted across different cases, and what concessions they have made under oath.
Federal Rule of Civil Procedure 26(a)(2)(B)(v) formalizes this interest by requiring retained expert witnesses to include in their reports a list of all other cases in which they testified as an expert at trial or by deposition in the previous four years. That rule is best understood as a locating mechanism — it helps the opposing party find prior testimony. It does not, by itself, authorize any particular use of the transcripts once found.
That distinction matters more than it might seem.
What Does "Reusing" a Prior Transcript Actually Mean?
Why the four-act framework matters
Research into this question suggests that litigation teams often blur four legally distinct acts together:
Discovering that prior testimony exists
Obtaining a copy of the transcript
Analyzing it internally for research, vetting, or cross-prep
Filing, quoting, or offering it in the new case
Each step involves different rules, different risks, and different gatekeepers. Federal evidence law — Rules 32, 613, 801(d), 804(b)(1), 702, 703, 705, and 403 — becomes most important at step four. But the compliance questions about whether the team was entitled to have and use the material at all arise at steps two and three, long before anything is filed.
A team that legally obtained a transcript in one matter may still be prohibited from reusing it in another matter by a protective order, a HIPAA restriction, an engagement contract, or an ethics obligation.
Those constraints are often the deciding factor before evidentiary rules ever come into play.
Is the Transcript Public or Discovery-Only? It Makes a Big Difference.
Why source provenance is the first question to ask
The single most important initial question is: where did this transcript come from?
The U.S. Supreme Court's decision in Seattle Times Co. v. Rhinehart, 467 U.S. 20 (1984) established that pretrial depositions and interrogatories are not ordinarily public components of a civil trial. Valid protective orders issued under FRCP Rule 26(c) can — and frequently do — restrict how discovery materials are disseminated, including limiting use to "this litigation only."
By contrast, materials that were actually filed in court in connection with adjudication may carry a stronger presumption of public access as judicial records, subject to whatever sealing orders or redaction requirements apply.
Whether the material was publicly filed is therefore a threshold question that shapes every subsequent analysis.
A practical source-by-source breakdown — based on available research:
Source | Typical Risk Level | Key Issues |
|---|---|---|
Same firm, same client, prior matter | Lower | Still check the prior protective order and any PHI |
Same firm, different client | Higher | Ethics rules on cross-client confidentiality apply |
Carrier archive, multiple insureds | Higher | Panel-counsel agreements, insured confidentiality |
Public court filing (transcript excerpt) | Lower | Rule 5.2 redactions, sealing orders still matter |
Discovery-only, "this litigation only" order | High | Direct prohibition on reuse in new matters |
Court reporter / transcript vendor | Varies | May be subject to contract license terms |
Rough draft or realtime feed | Medium-High | Likely not certified; may carry additional restrictions |
Note: This table reflects general patterns identified in research and is not a substitute for reviewing the specific documents, orders, and agreements governing each matter.
When Can a Prior Transcript Be Used in a New Case?
The evidentiary framework — a summary
If the team lawfully holds the transcript and no external restriction prohibits reuse, the Federal Rules of Evidence and Civil Procedure govern how and whether it can be used in litigation. Research identifies several distinct pathways, each with its own conditions:
Impeachment (Rule 613): Prior inconsistent statements from a deposition can be powerful impeachment tools. Federal Rule of Evidence 613, as amended in 2024, generally requires that the witness be given an opportunity to explain or deny the prior statement, and that the adverse party have an opportunity to examine the witness about it.
The transcript itself is relevant for preparation; whether it is admissible as extrinsic evidence depends on meeting those procedural conditions.
Substantive use — witness testifying (Rule 801(d)(1)(A)): If the expert actually testifies in the new case and is subject to cross-examination, a prior inconsistent statement made under penalty of perjury in a deposition may be admissible as non-hearsay under Rule 801(d)(1)(A). This is often the cleanest path for using prior deposition content substantively.
Former testimony — unavailable witness (Rule 804(b)(1)): If the expert is unavailable, former testimony may be admissible under Rule 804(b)(1) only if the party against whom it is offered — or, in civil cases, that party's predecessor in interest — had an opportunity and similar motive to develop the testimony when it was originally given. This is a meaningful limitation.
Same-case deposition in later action (Rule 32(a)(8)): FRCP Rule 32(a)(8) permits use of a deposition from an earlier action in a later action "involving the same subject matter between the same parties, or their representatives or successors in interest." This rule also preserves broader use where the Federal Rules of Evidence allow it.
Daubert and Rule 702 motion practice: Amended Rule 702 requires the proponent to show, more likely than not, that expert testimony rests on sufficient facts, reliable principles, and a reliable application to the case. Prior testimony about an expert's methodology can be highly relevant in challenging or defending admissibility, subject to Rule 403's balancing test.
None of these rules resolves the threshold question of whether the team was entitled to possess and use the transcript in the first place.
What Does HIPAA Mean for Prior Deposition Transcripts?
When protected health information changes the analysis
If a prior expert deposition transcript or attached expert report contains individually identifiable health information — diagnoses, treatment details, medical chronology, claimant identifiers — it may constitute Protected Health Information (PHI) under HIPAA's Privacy Rule, 45 C.F.R. Part 164.
45 C.F.R. § 164.512(e) governs disclosures for judicial and administrative proceedings. The key point that research surfaces: PHI disclosed for one litigation proceeding is not automatically available for reuse in a different proceeding.
If the original disclosure was made pursuant to a court order, the covered entity may disclose only the PHI expressly authorized by that order. If it was made pursuant to a subpoena or lawful process without a court order, there must have been satisfactory assurance of notice to the individual or a "qualified protective order" — and that order must prohibit use or disclosure outside the specific litigation for which the PHI was requested, and require return or destruction at the end of that proceeding.
This means a transcript from Case A that contains patient-specific PHI is generally not something a team can straightforwardly repurpose in Case B without a fresh authorization path, true de-identification, or additional counsel review.
Whether a particular transcript crosses this threshold depends on its actual contents, not on assumptions about what it might contain.
HHS has also clarified that cloud-based vendors who create, receive, maintain, or transmit ePHI on behalf of a covered entity or business associate may themselves qualify as business associates — even if the vendor's system is encrypted and the vendor cannot read the data. Litigation teams evaluating AI-based transcript tools should consider whether a Business Associate Agreement (BAA) is required before uploading PHI-containing materials.
What Do Attorney Ethics Rules Add?
The layer most teams underestimate
Even where no protective order or HIPAA rule technically prohibits reuse, attorney professional responsibility rules impose independent constraints that research suggests are frequently underestimated.
ABA Model Rule 1.6 prohibits revealing information relating to a client's representation without consent or another applicable basis. Model Rule 1.8(b) prohibits using client information to that client's disadvantage without informed consent — and commentary makes clear this applies when information benefits a different client. Model Rule 1.9(c) bars using former client information to that client's disadvantage unless the information has become generally known.
The practical implication: a firm may generally reuse its general know-how and publicly available information about an expert across matters. Reusing a former client's confidential documents, restricted discovery materials, or matter-specific work product to benefit a different client is a much harder case to make.
These duties extend to how firms use technology. ABA Formal Opinion 512 — the ABA's 2024 formal guidance on generative AI — applies ordinary duties of competence, confidentiality, candor, and supervision to AI tools. Multiple state bar associations, including in California, Florida, New York, Pennsylvania, and the District of Columbia, have issued similar guidance. The consistent message: lawyers may use AI tools, but they must protect confidential information, understand the tool's capabilities and limitations, verify outputs, and supervise vendors.
Uploading restricted discovery materials, PHI-containing transcripts, or a former client's confidential materials into an AI tool that lacks appropriate security, retention controls, or contractual confidentiality protections may independently violate these obligations — regardless of what the evidentiary rules say.
What About Rough Drafts and Realtime Transcripts?
A distinction that often gets missed
Not all deposition transcripts are the same product. Research surfaces an important distinction that litigation teams sometimes overlook.
A certified final transcript — signed and certified by the court reporter — is a different thing from a rough draft or realtime feed. Industry guidance from the National Court Reporters Association (NCRA) treats uncertified draft transcripts as a distinct product from the final certified transcript. Rough drafts may contain errors that have not been corrected through the certification process. Realtime feeds and synchronized video packages may carry additional contractual or licensing restrictions.
The practical consequence: using a rough draft or uncertified realtime transcript as if it were a final, authoritative record of what was said — whether in analysis, cross-prep, or any court-facing document — introduces both accuracy risk and potential contract risk. Where possible, teams should prefer certified final transcripts for any purpose that could eventually connect to filed materials, and should capture which type of transcript they are working with at the time of intake.
A Pre-Reuse Checklist for Litigation Teams
Before uploading, sharing, or building from a prior expert deposition transcript in a new matter, research suggests working through these questions — in consultation with counsel as needed:
Source: Is this transcript from a public court filing, or was it exchanged only in discovery?
Protective order: Is there a "this litigation only" restriction, confidentiality designation, AEO marking, or sealing order?
PHI: Does the transcript contain medical records, diagnoses, patient identifiers, or treatment information?
Client relationship: Is this the same client and same matter authorization, or a different client or insured?
Contracts: Are there engagement letter terms, panel-counsel guidelines, vendor license terms, or expert-retention agreements that restrict reuse?
Transcript type: Is this a certified final transcript, a rough draft, or a realtime feed?
Intended use: Is this for internal research only, impeachment prep, Daubert motion practice, or potential filing?
Attorney review: Has counsel assessed whether the use is permissible before any court-facing step?
No checklist substitutes for legal judgment. But working through these questions systematically is a reasonable starting point for identifying where the risks are highest.
How newcase.ai Approaches This Problem
Before a litigation team can decide whether prior case material is useful, it first has to know what exists, where it came from, and how it relates to the current matter.
That is the first problem newcase.ai is built to solve.
Prior expert testimony is often scattered across internal firm archives and public dockets: prior matters, carrier files, deposition repositories, and individual attorney folders. Even when the materials are technically available, it can be difficult to know which transcripts are worth reviewing.
newcase.ai helps litigation teams turn that scattered material into a structured, searchable, attorney-supervised research workflow.
The platform helps teams cluster, filter, and cross-reference expert testimony across prior matters and public sources. Instead of manually searching transcript by transcript, attorneys can identify patterns across an expert’s prior testimony, surface potentially relevant concessions, compare opinions across cases, and prioritize the materials most likely to matter for deposition prep, expert vetting, Daubert research, or impeachment analysis.
newcase.ai is designed around the principle that the safest architecture for litigation-intelligence work is a private, matter-specific archive — not a pooled cross-customer database.
That means each customer's transcripts and expert materials stay within that customer's workspace. Documents carry metadata for source, matter, client, confidentiality designation, PHI status, and transcript type. Matter-level access controls limit who can query which materials. No customer data is used to train models. Where PHI is involved, BAA workflows are available.
The platform's Expert Witness Research and Deposition Prep features are built to support attorney-supervised analysis — generating source-linked outputs with page and line citations so attorneys can verify every analytical claim before it informs a filing, a cross outline, or a settlement position.
Frequently Asked Questions
Can I use a prior expert's deposition transcript to prepare for their deposition in a new case?
Generally, internal use of lawfully held prior transcripts for research and deposition preparation is not prohibited by the Federal Rules of Evidence — but whether the use is permissible depends on whether the team was entitled to have and retain the material for that new purpose. If the transcript was produced under a "this litigation only" protective order, or contains PHI from a prior case, the internal use itself may be restricted even before anything is filed. Attorneys should review the source, any protective orders, and applicable ethics rules before using prior transcripts for cross-prep in a new matter.
Does FRCP Rule 26 give me the right to use an expert's prior transcripts?
Rule 26(a)(2)(B)(v) requires experts to disclose the cases in which they testified over the prior four years — which helps locate prior testimony. But Rule 26 is a locating mechanism, not a reuse authorization. The right to discover that prior testimony exists is different from the right to possess a transcript, analyze it across matters, or offer it in court. The reuse question is governed by protective orders, HIPAA, ethics rules, and the evidentiary rules — not by Rule 26's disclosure requirement alone.
What makes a deposition transcript subject to HIPAA?
A transcript may contain PHI if it includes individually identifiable health information — diagnoses, treatment records, medical chronology, claimant identifiers, or attached medical exhibits. If a covered entity or business associate disclosed PHI under a court order or qualified protective order for a specific litigation proceeding, that disclosure does not authorize reuse of the same PHI in a different proceeding. Teams handling transcripts from medical malpractice, workers' comp, personal injury, or other medically intensive cases should assume PHI may be present and conduct a review before cross-matter use.
Is a rough draft deposition transcript the same as a final certified transcript?
No. A rough draft or realtime feed is not the certified final product. It may contain uncorrected errors and may be subject to different contractual terms from the court reporter or vendor. Industry guidance from the NCRA distinguishes rough drafts from certified final transcripts. Using a rough draft as if it were an authoritative final record introduces both accuracy risk and potential contract risk. Where the intent is to rely on specific testimony — for cross-prep, motion practice, or any court-facing purpose — the certified final transcript is the appropriate source.
Can our firm's AI vendor receive deposition transcripts containing PHI?
If the vendor creates, receives, maintains, or transmits ePHI on behalf of a covered entity or business associate — which may include law firms that themselves serve as business associates — HIPAA may require a signed Business Associate Agreement (BAA) before that vendor receives PHI-containing transcripts. HHS guidance clarifies that this applies even to cloud service providers who cannot read the data they store. A BAA is a necessary condition for certain uses, but it does not by itself authorize cross-matter reuse of PHI originally disclosed for a specific proceeding.
Closing
Prior expert deposition transcripts are among the most valuable research assets in litigation. They are also among the most legally constrained. The question is not just whether a team can find prior testimony — it is whether the team was entitled to have the transcript, what restrictions attach to it, what it contains, and what the team intends to do with it.
Research suggests that the most defensible approach is not to treat every transcript in a firm's possession as a general-purpose institutional asset. It is to work with tools and workflows that track provenance, enforce matter-level access controls, flag PHI and confidentiality designations, and require attorney review before any transcript analysis informs something court-facing.
That is a safer way to get the value of expert intelligence — without assuming that access equals permission.
If you're evaluating how your team handles prior expert materials, newcase.ai's Expert Witness Research is built around the principle that source-linked, attorney-supervised analysis is the right standard for this work.
Sources and References
